中西医结合治疗老年晚期非小细胞肺癌疗效观察

Clinical observation on treating advanced non-small cell lung cancer in elderly patients in the integrative medicine

目的:研究观察中西医结合治疗老年晚期非小细胞肺癌临床疗效。方法:选取2014年8月-2016年1月在我院接受治疗的120例老年晚期非小细胞肺癌患者作为研究对象,随机将患者分为中医治疗组、化疗组以及中西医结合治疗组,每组40例,每个周期21d,共治疗4个周期。以Karnofsky评分、消化道不良反应、骨髓抑制、中位生存时间、治疗有效率作为临床效果评判依据。结果:中医治疗组、化疗组以及中西医结合治疗组的Karnofsky评分分别为50.0%、42.5%、82.5%,中西医结合治疗组明显较高;消化道不良反应发生率分别为37.5%、87.5%、40.0%,中医治疗组最低,其次为中西医结合治疗组;骨髓抑制发生率分别为7.5%、40.0%、10.0%,中医治疗组最低,其次为中西医结合治疗组;中位生存时间分别为7.2个月、7.1个月、12.5个月,中西医结合治疗组延长明显;总有效率分别为40.0%、37.5%、60.0%,中西医结合治疗组明显较高。结论:通过中西医结合治疗老年晚期能够有效缓解临床症状、降低毒副反应、延长生存期、提高生活质量,值得临床推广。

Objective:To study clinical efficacy of the integrative medicine on advanced non-small cell lung cancer.Methods:120patients were randomly divided into the TCM group,chemotherapy group and the integrative medicine group,40patients in each group,21days as one course,for4courses.Clinical efficacy was decided by Karnofsky score,gastrointestinal adverse reactions,bone marrow suppression,median survival time,efficiency.Results:The Karnofsky scores were50.0%,42.5%and82.5%respectively in the treatment group,chemotherapy group and the integrative medicine group;the incidence of gastrointestinal adverse reactions was37.5%,87.5%and40.0%respectively.The incidence of myelosuppression was7.5%,40.0%and10.0%respectively.The survival time was7.2months,7.1months,12.5months respectively.The total efficiency was40.0%,37.5%,60.0%respectively.Conclusion:The integrative medicine can effectively alleviate the clinical symptoms,reduce the toxicity,prolong survival,improve the quality of life,and is worthy of clinical promotion.